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Baseline infl ammation is not predictive of periprocedural troponin elevation 
after elective percutaneous coronary intervention
Abstract High-sensitivity C-reactive protein predicts future 
cardiovascular events in both healthy individuals and 
patients with unstable and stable coronary syndromes. Few 
data are available about the incidence and the relation to 
infl ammation of troponin elevation following percutaneous 
coronary intervention (PCI), a potential predictor of long-
term outcome. We sought to confi rm the impact of emboli-
zation on long-term outcome and evaluate the ability of 
baseline infl ammation to predict troponin elevation induced 
by PCI. We prospectively analyzed 200 patients treated by 
PCI for stable or Braunwald IIA class unstable angina. The 
patients were recruited between January 1997 and May 
1999, and the population was followed during a mean 
follow-up of 32 months. Major adverse cardiac events 
(MACEs) were defi ned as the occurrence of death, myocar-
dial infarction or recurrent angina requiring repeat PCI, or 
coronary artery bypass grafting. During the follow-up 
period, 58 MACEs were observed. By multivariate analysis, 
independent predictors for the occurrence of MACEs were 
unstable angina and troponin I level after PCI (P < 0.0001 
for both). No correlation was found between baseline 
infl ammation and signifi cant troponin I elevation post PCI 
and by multivariate analysis, no biological variable was a 
predictor of troponin I elevation post PCI. Baseline infl am-
mation cannot predict onset of minor myonecrosis damage 
(expressed by troponin elevation) induced by PCI, a signifi -
cant predictor of long-term outcome in this setting.
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Introduction
Among various studied infl ammatory markers,1 high-sen-
sitivity C-reactive protein is an infl ammatory marker that 
predicts future cardiovascular events in both healthy indi-
viduals with no history of cardiovascular disease and in 
patients with unstable as well as stable coronary syn-
dromes.2–5 Preprocedural high-sensitivity C-reactive protein 
has been found to be an independent predictor of adverse 
cardiac events in patients treated by elective percutaneous 
coronary intervention (PCI) with or without a stent6,7 as 
well as in patients treated by surgical revascularization.8 
Infl ammatory reactivity has been found to be a powerful 
predictor of complication in stable angina treated by 
PCI.9
Troponin elevation in the setting of elective intervention 
has been linked to higher mortality in several clinical set-
tings.10–12 Except for local anatomic characteristics13 (i.e., 
side branch, degree of atheroma burden, evidence of throm-
bus in angiography), the predisposing factors that lead to 
periprocedural minor myonecrosis are not fully established. 
Especially, it is unknown if arterial infl ammation and 
heightened infl ammatory state could favor embolization 
and could be responsible for short- or long-term complica-
tions. Enhanced infl ammatory activity could be able to 
favor myocardial damage by various mechanisms (facilitat-
ing local recruitment of infl ammatory cells, altering small 
vessel function, destabilizing coronary plaque, promoting 
endothelial activation by a decreased nitric oxide bioavail-
ability). Despite these different theoretical mechanisms, the 
inter-relationship between these two parameters is not fully 
understood. The purposes of this study were to evaluate the 
long-term prognostic impact of embolization in patients 
treated by PCI and afterward analyze the relation between 
baseline infl ammation and postprocedural troponin I 
elevation.




Between January 1997 and May 1999, we prospectively 
analyzed 200 patients referred for coronary angioplasty for 
stable or Braunwald class IIa unstable angina. They under-
went PCI of one or more coronary stenoses. The exclusion 
criteria were patients with suspected or confi rmed acute 
coronary syndrome (with or without ST segment elevation) 
at presentation or within 6 months, patients treated for 
restenosis, total occlusion or coronary graft, coronary artery 
bypass grafting, or PCI within 6 months, heart failure in 
New York Heart Association class ≥3, abnormal renal 
function, or known malignant or infl ammatory disorders. 
Follow-up was obtained in all patients by inspection of the 
medical records. Major adverse cardiac events (MACEs) 
were defi ned as the occurrence of death of any cause, myo-
cardial infarction (with or without ST segment elevation), 
and any coronary revascularization (surgery and/or percu-
taneous). Myocardial infarction was defi ned as the occur-
rence of typical chest pain associated with an increase of 
creatine kinase-MB at least three times above the upper 
normal limit or with the development of new pathological 
Q waves on the electrocardiogram. All patients have given 
their informed consent and the study was approved by the 
local ethics committee.
Blood sampling
A fasting morning blood sample was taken from each 
patient on the day before and 24 h after the angioplasty. 
High-sensitivity C-reactive protein assays were measured 
by rate nephelometry using a commercially available kit 
(Behring N latex C-reactive protein mono Analyzer, 
Behring Diagnostic, Marburg, Germany). The lower detec-
tion limit was 0.175 mg/l. Troponin I assays were measured 
by a commercial microparticle enzyme immunoassay kit 
(AxSYM Abbott Laboratories, Abbott Park, IL, USA). 
The normal value is ≤0.5 μg/l (n = 437).
Coronary angiography
Selective coronary angiography was performed via the 
femoral route using a 6-F introducer sheath. Serial coronary 
angiograms of the left and right coronary arteries were 
performed after intracoronary administration of isosorbide 
dinitrate (0.2–0.4 mg). After diagnostic evaluation, angio-
plasty with or without stenting was performed. Heparin 
(70 U/kg) was given before the introduction of the guide 
wire. No patient received glycoprotein IIb/IIIa inhibitors, 
but all were pretreated with ticlopidine (500 mg) at least 4 h 
before intervention. All patients were treated with aspirin 
indefi nitely and ticlopidine 250 mg twice daily was added 
for 4 weeks in the patients treated by stenting.
Statistical analysis
Results are expressed as mean ± standard deviation (SD) 
for quantitative variables while frequencies and proportions 
(%) were used for categorical variables. Mean values were 
compared by the Student t-test (for normally distributed 
variables) and by the Wilcoxon test otherwise. Proportions 
were compared by the chi-squared test for contingency 
tables. Cox proportional hazards regression analysis was 
used to test the effect of covariates on major adverse cardiac 
event-free interval and to derive hazard ratio (HR) with 
95% confi dence interval (95% CI). Multivariate logistic 
regression was used to detect clinical and/or biological pre-
dictor factors of signifi cant troponin I elevation. Odds ratio 
(OR) with 95% CI were also given. Results were consid-
ered signifi cant at the 5% critical level (P < 0.05). All 
calculations were performed using SAS (version 9.1 for 
Windows; SAS Institute, Cary, NC, USA) and S-PLUS 
(version 6.2; Insightful, Seattle, WA, USA) statistical 
packages.
Results
The clinical and biological characteristics of the studied 
population are listed in Table 1. Mean baseline high-
sensitivity C-reactive protein levels were 4.21 ± 5.80 mg/l 
and were higher in smokers (4.29 ± 5.02 vs 4.06 ± 7.03 mg/l, 
P = 0.048) and in patients with unstable angina (5.42 ± 
6.24 vs 4.06 ± 5.73 mg/l, P = 0.044). Baseline leukocyte count 
was higher in current smokers (7.74 ± 2.06 vs 6.89 ± 
1.70 103/mm3, P = 0.0018) while baseline fi brinogen was 
higher in diabetic patients (3.35 ± 0.80 vs 2.96 ± 0.70 g/l, 
P = 0.014).
Table 1. Clinical and biological characteristics of the studied 
population
Variable n = 200
Pre-PCI Post-PCI
Men 161 (80.5%)
Age (years) 64 ± 9.6
Current smoker 130 (65%)
Hypertension 106 (53%)
Hyperlipidemia  98 (49%)
Diabetes mellitus  31 (15.5%)
Stable angina 178 (89%)
Ejection fraction <60%  47 (23.5%)
Stent 103 (51.5%)
Statin treatment  31 (15.6%) 175 (87.5%)
Total cholesterol (mg/dl) 225 ± 44 212 ± 46
Triglycerides (mg/dl) 192 ± 14 214 ± 13
hsCRP (mg/l) 4.21 ± 5.8 8.29 ± 9.6
White blood count (103/mm3) 7.45 ± 1.98
Fibrinogen (g/l) 3.01 ± 0.73 3.22 ± 0.65
Creatine kinase MB (μg/l) 2.29 ± 1.32 8.3 ± 16
Troponin I (μg/l) 0.22 ± 0.61 2.33 ± 6.7
Values expressed as mean ± SD for age and as mean ± SEM for other 
values
hsCRP, high-sensitivity C-reactive protein; PCI, percutaneous coro-
nary intervention
 269
Mean baseline troponin I was 0.22 ± 0.61 μg/l, that it is 
to say within normal range (normal value ≤0.5 μg/l, n = 437) 
while post intervention mean values were 2.33 ± 6.7 μg/l. 
Patients treated with stent presented higher postinter-
vention troponin I levels (3.58 ± 8.90 vs 1.01 ± 2.41 μg/l, 
P = 0.0002). Forty-four patients (22%) presented more than 
threefold elevation of troponin I after intervention. Those 
patients presented higher baseline troponin I levels (0.58 ± 
1.02 vs 0.12 ± 0.37 μg/l, P < 0.0001) while their baseline 
C-reactive protein levels were higher but without reaching 
statistical signifi cance (5.85 ± 8.88 vs 3.76 ± 4.53 μg/l, 
P = 0.87).
During the follow-up period (mean = 30.8 ± 16.1 months), 
29% of the studied population presented a major cardiac 
adverse event: 9 patients died, 12 patients presented acute 
myocardial infarction (2 Q-wave, 10 non–Q Wave), 5 
patients underwent coronary artery bypass grafting for 
recurrent ischemia, 13 patients were treated by PCI on 
another lesion than the initial one, and 26 patients pre-
sented angiographic restenosis in whom 19 were treated by 
repeat PCI.
In multivariate analysis, the predictors of MACEs were 
unstable angina (HR: 6.58 [3.43–12.6]) and troponin I post 
intervention (HR: 1.10 [1.05–1.15]) (Table 2). No relation 
was found between baseline high-sensitivity C-reactive 
protein levels and signifi cant elevation of troponin I induced 
by PCI (up to threefold the normal values). Neither was 
baseline C-reactive protein level correlated to delta tropo-
nin, defi ned as troponin I level post PCI minus troponin I 
pre PCI.
By multivariate analysis, the only predictor of signifi cant 
troponin I elevation post intervention was stent implanta-
tion (OR: 2.78 [1.18–6.56]). None of the studied biological 
parameters including especially baseline high sensitivity C-
reactive protein (P = 0.53) were predictors of troponin I 
elevation.
Discussion
In our study, as in previously published reports, we report 
a signifi cant prognostic impact of troponin I elevation after 
intervention on long-term outcome.10,11,14,15. These troponin 
elevations may be in part closely related the procedure 
(embolization and/or closure of side branch). Unfortu-
nately, even careful angiographic assessment cannot com-
pletely predict which patients will develop periprocedural 
embolization responsible for microvascular obstruction and 
necrosis. Moreover, detection of such a predisposing situa-
tion can only be made in the catheterization laboratory, 
ruling out the possibility of preinvasive optimal pharmaco-
logical preparation. Lesion morphology provides some 
prognostic information particularly in regard to the proce-
dure-related risk but troponin is a more powerful predictor 
of cardiac risk than angiographic characteristics.16
Nevertheless, underlying predisposing factors that lead 
to minor periprocedural myocardial infarction could also 
play a role.17,18 Systemic and arterial infl ammation favoring 
embolization is one of these potential predisposing factors 
that would be available prior to the catheterization labora-
tory. In this hypothesis, baseline C-reactive protein levels 
should be able to predict signifi cant troponin elevation 
post intervention. Contrary to Saadeddin et al.,19 we failed 
in this study to demonstrate this predictive ability of 
baseline infl ammation. In this previous report, which 
included a limited number of patients (n = 85), the authors 
used an arbitrary cutoff level of high-sensitivity C-reactive 
protein that was quite elevated (6 mg/l) to defi ne signifi cant 
enhanced infl ammation status.
Periprocedural myonecrosis predicts outcome although 
the exact threshold is undetermined, varying across studies. 
Therapies liable to reduce such minor necrosis also reduce 
long-term complications.20–22 In the ARMYDA study20 
pretreatment with Atorvastatin, a drug with known anti-
infl ammatory properties,23 signifi cantly reduced procedural 
myocardial injury in an elective population but this effect 
was observed while C-reactive protein levels at the time of 
procedure were not signifi cantly different in the two groups. 
Periprocedural myonecrosis appears therefore as a target 
for therapy, and a preinvasive indicator of the susceptibility 
of subsequent event would be of great interest. In our 
report, baseline infl ammation does not demonstrate this 
property.
Stents usually lead to some degree of embolization, more 
frequently than does balloon angioplasty.24 This observa-
tion is confi rmed in this study.
Study limitations
Although the data were collected prospectively, this is a 
retrospective single-center analysis and is subject to the 
limitations of such analysis. This study involves a limited 
population with a relatively short follow-up. No drug-eluting 
stents were used. Our observations are not necessarily 
applicable to other clinical settings. Platelet function was 
not evaluated and therefore it is impossible to exclude that 
Table 2. Independent predictive factors of MACEs in multivariate analysis
Univariate analysis Multivariate analysis
P value Hazard ratio (95% CI) P value Hazard ratio (95% CI)
Unstable angina <0.0001 5.96 (3.42–10.38) <0.0001 6.58 (3.43–12.6)
Statin treatment 0.03 1.20 (0.61–2.37) NS
Troponin I post PCI <0.0001 1.08 (1.04–1.11) <0.0001 1.10 (1.05–1.15)
MACEs, major adverse cardiac events; PCI, percutaneous coronary intervention; CI, confi dence interval; NS, not signifi cant
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some patients could present aspirin resistance, a factor 
known to promote periprocedural myonecrosis.
Conclusions
Periprocedural minor myocardial necrosis is a frequent 
observation in this study. The troponin release occurring 
after PCI is an independent predictive factor of outcome. 
The predisposing factors that lead to periprocedural minor 
myonecrosis are not fully established. In this study, baseline 
infl ammation assessed by high-sensitivity C-reactive protein 
measurement is not able to predict the occurrence of such 
troponin release corresponding to embolization.
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